CHICAGO, March 3, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that the members of the management team will make presentations at two upcoming conferences:
- BIO-Europe Spring® 2014: March 11th at 2:45 pm CET, Turin, Italy
Corey Fishman, CFO/COO to present
- ROTH 26th Annual Conference: March 11th at 11:00 am PDT, Laguna Nigel, California
Paul R. Edick, CEO to present
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria.
Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.
CONTACT: Allison Wey Durata Therapeutics, Inc. Vice President, Investor Relations and Public Affairs (312) 219-7017 firstname.lastname@example.org
Source:Durata Therapeutics, Inc.